NRX Pharmaceuticals (NRXP) Goodwill (2025 - 2026)

NRX Pharmaceuticals' (NRXP) quarterly Goodwill came in at $1.8 million in Q1 2026, little changed on a QoQ basis from $1.8 million in Q4 2025.

NRX Pharmaceuticals (NRXP) Goodwill (2025 - 2026) Analysis & Trends

NRX Pharmaceuticals (NRXP) has 2 years of Goodwill data on file, last reported at $1.8 million in Q1 2026.

On a quarterly basis, Goodwill changed N/A year-over-year to $1.8 million in Q1 2026; TTM through Mar 2026 was $1.8 million, a N/A change from a year earlier, with the FY2025 full-year figure at $1.8 million, changed N/A from the prior year.
Goodwill for Q1 2026 stood at $1.8 million, roughly flat from $1.8 million in the prior quarter.
Over the last five years, Goodwill for NRXP reached as high as $1.8 million in Q4 2025 and fell as low as $610000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,079.99 Bn	66,079.71 Bn	-
2	Nanobiotix	1,912.79 Bn	1,912.73 Bn	-
3	Akari Therapeutics	1,022.34 Bn	1,022.34 Bn	-
4	BeOne Medicines	471.68 Bn	466.89 Bn	1.35 Bn
5	Vertex Pharmaceuticals	122.31 Bn	115.06 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	70.24 Bn	61.49 Bn	3.31 Bn
7	Belite Bio	63.01 Bn	63.01 Bn	-
8	Argenx Se	56.02 Bn	50.83 Bn	1.41 Bn
9	Alnylam Pharmaceuticals	37.46 Bn	34.45 Bn	959.66 Mn
10	NRX Pharmaceuticals	118.31 Mn	111.61 Mn	437,000.00

Download Data